Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

BRENDA Home
show all | hide all No of entries

Information on EC 1.4.3.4 - monoamine oxidase and Organism(s) Rattus norvegicus and UniProt Accession P21396

for references in articles please use BRENDA:EC1.4.3.4
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
     1 Oxidoreductases
         1.4 Acting on the CH-NH2 group of donors
             1.4.3 With oxygen as acceptor
                1.4.3.4 monoamine oxidase
IUBMB Comments
A mitochondrial outer-membrane flavoprotein (FAD) that catalyses the oxidative deamination of neurotransmitters and biogenic amines . Acts on primary amines, and also on some secondary and tertiary amines. It differs from EC 1.4.3.21, primary-amine oxidase as it can oxidize secondary and tertiary amines but not methylamine. This enzyme is inhibited by acetylenic compounds such as chlorgyline, 1-deprenyl and pargyline but, unlike EC 1.4.3.21 and EC 1.4.3.22 (diamine oxidase), it is not inhibited by semicarbazide.
Specify your search results
Select one or more organisms in this record: ?
This record set is specific for:
Rattus norvegicus
UNIPROT: P21396
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)
Word Map
The taxonomic range for the selected organisms is: Rattus norvegicus
The expected taxonomic range for this enzyme is: Bacteria, Eukaryota, Archaea
Reaction Schemes
Synonyms
monoamine oxidase, mao-b, mao-a, monoamine oxidase a, mao a, mao b, monoamine oxidase b, monoamine oxidase-b, monoamine oxidase-a, semicarbazide-sensitive amine oxidase, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
monoamine oxidase B
-
monoamine oxidase-A
-
adrenaline oxidase
-
-
-
-
amine-oxygen oxidoreductase
-
-
epinephrine oxidase
-
-
-
-
MAO A
MAO B
MAO-A
MAO-B
monoamine oxidase
monoamine oxidase A
monoamine oxidase B
monoamine oxidase-B
-
monoamine:O2 oxidoreductase (deaminating)
-
-
-
-
semicarbazide-sensitive amine oxidase
-
-
serotonin deaminase
-
-
-
-
tyraminase
-
-
-
-
tyramine oxidase
-
-
-
-
additional information
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
RCH2NHR' + H2O + O2 = RCHO + R'NH2 + H2O2
show the reaction diagram
catalysis occur via proton abstraction mechanisms
RCH2NHR' + H2O + O2 = RCHO + R'NH2 + H2O2
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Deamination
-
-
-
-
redox reaction
-
-
-
-
oxidation
-
-
-
-
reduction
-
-
-
-
SYSTEMATIC NAME
IUBMB Comments
amine:oxygen oxidoreductase (deaminating)
A mitochondrial outer-membrane flavoprotein (FAD) that catalyses the oxidative deamination of neurotransmitters and biogenic amines [3]. Acts on primary amines, and also on some secondary and tertiary amines. It differs from EC 1.4.3.21, primary-amine oxidase as it can oxidize secondary and tertiary amines but not methylamine. This enzyme is inhibited by acetylenic compounds such as chlorgyline, 1-deprenyl and pargyline but, unlike EC 1.4.3.21 and EC 1.4.3.22 (diamine oxidase), it is not inhibited by semicarbazide.
CAS REGISTRY NUMBER
COMMENTARY hide
9001-66-5
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
1-methylhistamine + H2O + O2
?
show the reaction diagram
reaction with MAO-A at 1 mM substrate, no activity at 0.1 mM substrate
-
-
?
1-methylhistamine + O2 + H2O
1-methyl-1H-imidazol-4-ylacetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
reaction with MAO-A
-
-
?
4-aminomethylpyridine dihydrochloride + H2O + O2
?
show the reaction diagram
3% substrate activity of 1 mM 4-aminomethylpyridine dihydrochloride as percentage of the activity of the best substrate (serotonin, 1 mM) for various amine oxidases
-
-
?
4-tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
4-tyramine + H2O + O2
2-(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
5-hydroxytryptamine + H2O + O2
?
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
benzylamine + O2 + H2O
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
beta-phenylethylamine + O2 + H2O
beta-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
histamine + H2O + O2
?
show the reaction diagram
reaction with MAO-A at 1 mM substrate, no activity at 0.1 mM substrate
-
-
?
histamine + O2 + H2O
1H-imidazol-4-ylacetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
p-tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
MAO-B
-
-
?
p-tyramine + H2O + O2
4-hydroxyphenylethanal + NH3 + H2O2
show the reaction diagram
phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
serotonin + O2 + H2O
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
5-hydroxytryptamine, MAO-A
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
tyramine + O2 + H2O
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
1-(4-bromophenyl)methanamine + H2O + O2
4-bromobenzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
1-(4-chlorophenyl)methanamine + H2O + O2
4-chlorobenzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
1-(4-fluorophenyl)methanamine + H2O + O2
4-fluorobenzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
1-(4-methoxyphenyl)methanamine + H2O + O2
4-methoxybenzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
1-(4-methylphenyl)methanamine + H2O + O2
4-methylbenzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
1-methylhistamine + H2O + O2
1-methyl-1H-imidazol-4-ylacetaldehyde + NH3 + H2O2
show the reaction diagram
reaction with MAO-B at 1 mM substrate, no activity at 0.1 mM substrate
-
-
?
1-methylhistamine + O2 + H2O
1-methyl-1H-imidazol-4-ylacetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
1-[4-(trifluoromethyl)phenyl]methanamine + H2O + O2
4-(trifluoromethyl)benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
4-aminomethylpyridine dihydrochloride + H2O + O2
?
show the reaction diagram
4% substrate activity of 1 mM 4-aminomethylpyridine dihydrochloride as percentage of the activity of the best substrate (1 mM) for various amine oxidases
-
-
?
4-dimethylaminophenethylamine + H2O + O2
?
show the reaction diagram
substrate of MAO-B
-
-
?
4-dimethylaminophenylethylamine + H2O + O2
?
show the reaction diagram
-
substrate of MAO-B
-
-
?
4-hydroxy-3-methoxy-2-phenylethylamine + H2O + O2
?
show the reaction diagram
-
-
-
-
r
4-methoxy-2-phenylethylamine + H2O + O2
?
show the reaction diagram
-
-
-
-
r
4-tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
4-tyramine + H2O + O2
2-(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
benzylamine + H2O + O2
benzylaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + O2 + H2O
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
beta-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
beta-phenylethylamine + H2O + O2
beta-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
beta-phenylethylamine + O2 + H2O
beta-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
dopamine + H2O + O2
(3,4-dihydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
histamine + H2O + O2
1H-imidazol-4-ylacetaldehyde + NH3 + H2O2
show the reaction diagram
reaction with MAO-B at 1 mM substrate, no activity at 0.1 mM substrate
-
-
?
histamine + O2 + H2O
1H-imidazol-4-ylacetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
kynuramine + H2O + O2
?
show the reaction diagram
-
-
-
?
kynuramine + O2
4-hydroxyquinoline + NH3 + H2O2
show the reaction diagram
-
-
-
?
methoxytryptamine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
p-tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
tryptamine + H2O + O2
1-H-indol-3-yl-acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
tyramine + H2O + O2
4-hydroxyphenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
tyramine + O2 + H2O
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
additional information
?
-
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
MAO-A
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
MAO-A
-
-
?
phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
MAO-A
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
MAO-A
-
-
?
4-dimethylaminophenylethylamine + H2O + O2
?
show the reaction diagram
-
substrate of MAO-B
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzylaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
substrate of MAO-A
-
-
?
additional information
?
-
the enzyme catalyzes the degradation of neurotransmitters in the central nervous system and is the target for anti-depression drug design
-
-
?
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
flavin
flavin
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(4-[[bis(methylene)(4-methylphenyl)-lambda6-sulfanyl]oxy]phenoxy)hydrazine
0.1 mM, complete inhibition
(6-benzyloxy-2-naphthyl)-2-aminopropane
-
(6-butoxy-2-naphthyl)-2-aminopropane
-
(6-ethoxy-2-naphthyl)-2-aminopropane
-
(6-methoxy-2-naphthyl)-2-aminopropane
-
(6-methylthio-2-naphthyl)isopropylamine
-
(6-propoxy-2-naphthyl)-2-aminopropane
-
1-(1-naphthyl)-2-aminopropane
-
1-(2-naphthyl)-2-aminopropane
-
1-(3,5-diethoxypyridin-4-yl)methanamine dihydrochloride
-
1-(4-benzyloxyphenyl)-2-aminopropane
-
1-(4-butoxyphenyl)-2-aminopropane
-
1-(4-ethoxyphenyl)-2-aminopropane
-
1-(4-methoxy-phenyl)-2-aminopropane
-
1-(4-methylthiophenyl)-2-aminopropane
-
1-(4-propoxyphenyl)-2-aminopropane
-
1-N-allylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-A
1-N-allylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor
1-N-ethylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-A
1-N-ethylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor
1-N-methylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-A
1-N-methylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor
1-N-phenylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-A
1-N-phenylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor
1-phenyl-2-aminopropane
-
1-thiocarbamoyl-3-(4-bromophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
1-thiocarbamoyl-3-(4-bromophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
1-thiocarbamoyl-3-(4-methylphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
1-thiocarbamoyl-3-(4-methylphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
1-[3-(benzyloxy)-5-ethoxypyridin-4-yl]methanamine dihydrochloride
-
11H-indolo[3,2-c]cinnoline
-
2-(3-nitrophenyl)-9H-indeno[2,1-d]pyrimidin-9-one
5% inhition at 0.001 mM
2-bromo-N-(2-morpholinoethyl)nicotinamide
-
2-bromo-N-(3-morpholinopropyl)nicotinamide
-
2-chloro-6-methyl-N-(2-morpholinoethyl)nicotinamide
-
2-chloro-6-methyl-N-(3-morpholinopropyl)nicotinamide
-
2-chloro-N-(2-morpholinoethyl)nicotinamide
-
2-chloro-N-(3-morpholinopropyl)nicotinamide
-
2-hydroxy-N-(2-morpholinoethyl)nicotinamide
-
2-hydroxy-N-(3-morpholinopropyl)nicotinamide
-
2-methyl-9H-indeno[2,1-d]pyrimidin-9-one
-
2-phenyl-2H-indeno[1,2-c]pyridazine-3,5-dione
46% inhibition at 0.05 mM
2-phenyl-5H-indeno[1,2-d]pyrimidine
-
2-phenyl-9H-indeno[2,1-d]pyrimidine
-
3,3'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dipropan-1-ol dihydrochloride
-
3,4-dimethyl-7-(2-phenoxyethoxy)-2H-chromen-2-one
pIC50 for MAO-A: 4.99
3,4-dimethyl-7-(2-phenylethyl)-2H-chromen-2-one
pIC50 for MAO-A: 5.15
3,4-dimethyl-7-phenoxy-2H-chromen-2-one
pIC50 for MAO-A: 4.5
3-(1-piperidinyl)-4-aminomethylpyridine dihydrochloride hemihydrate
-
3-(3-aminophenyl)-9H-indeno[1,2-e][1,2,4]triazin-9-one
12% inhibition at 0.01 mM
3-(3-nitrophenyl)-5H-indeno[2,1-e][1,2,4]triazin-5-one
3% inhibition at 0.01 mM
3-(3-nitrophenyl)-9H-indeno[1,2-e][1,2,4]triazin-9-one
23% inhibition at 0.01 mM
3-(4-fluorophenyl)-5-(2-naphthyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-acetylaminophenyl)-N-phenyl-4,5-dihydro-1H -pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methylphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N,5-diphenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N-methyl-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N-methyl-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N-methyl-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-amino-4-aminomethylpyridine dihydrochloride
-
3-cycloheptylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclohexylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclohexylmethylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclopentylamino-4-aminomethylpyridine dihydrochloride hemihydrate
-
3-cyclopropylamino-4-aminomethylpyridine dihydrochloride sesquihydrate
-
3-ethylamino-4-aminomethylpyridine dihydrochloride
-
3-methylamino-4-aminomethylpyridine dihydrochloride
-
3-phenyl-9H-indeno[1,2-e][1,2,4]triazin-9-one
21% inhibition at 0.01 mM
3-[(1-methylethyl)amino]-4-aminomethylpyridine dihydrochloride
-
3-[(4-fluorophenoxy)methyl]-5H-indeno[1,2-c]pyridazin-5-one
12% inhibition at 0.01 mM
4-(4-chlorophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
4-(aminomethyl)-N,N'-dibutylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N,N'-diethylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N,N'-dimethylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N-methylpyridine-3,5-diamine dihydrochloride
-
4-chloro-N-(2-morpholinoethyl)nicotinamide
-
4-chloro-N-(3-morpholinopropyl)nicotinamide
-
4-phenyl-5H-indeno[1,2-d]pyrimidin-5-one
-
4-[1-(cyclopropylcarbamothioyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
-
4-[1-(ethylcarbamothioyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
-
4-[2-[4-(benzyloxy)phenoxy]hydrazino]butanenitrile
0.1 mM, 39% inhibition
4-[3-(4-fluorophenyl)-1-(methylcarbamothioyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
-
5,6-dichloro-N-(2-morpholinoethyl)nicotinamide
-
5,6-dichloro-N-(3-morpholinopropyl)nicotinamide
-
5-(4-bromophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-bromophenyl)-3-(4-fluorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-bromophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-bromophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-bromo-N-(2-morpholinoethyl)nicotinamide
-
5-bromo-N-(3-morpholinopropyl)nicotinamide
-
5-chloro-6-hydroxy-N-(2-morpholinoethyl)nicotinamide
-
5-chloro-6-hydroxy-N-(3-morpholinopropyl)nicotinamide
-
6,11-dihydro-5H-benzo[a]carbazole
-
6-chloro-N-(2-morpholinoethyl)nicotinamide
-
6-chloro-N-(3-morpholinopropyl)nicotinamide
-
6-fluoro-N-(2-morpholinoethyl)nicotinamide
-
6-fluoro-N-(3-morpholinopropyl)nicotinamide
-
6-hydroxy-N-(2-morpholinoethyl)nicotinamide
-
6-hydroxy-N-(3-morpholinopropyl)nicotinamide
-
6-methyl-N-(2-morpholinoethyl)nicotinamide
-
6-methyl-N-(3-morpholinopropyl)nicotinamide
-
7-(2-hydroxy-2-phenylethyloxy)-3,4-dimethyl-2H-chromen-2-one
-
7-(3-chlorobenzyloxy)-3-methyl-2H-chromen-2-one
pIC50 for MAO-A: 4.9
7-(3-phenylprop-2-en-1-yloxy)-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-A: 4.5
7-(benzenesulfonylmethoxy)-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-A: 5.55
7-benzenesulfonyloxy-2H-chromen-2-one
pIC50 for MAO-A: 6.35
7-benzyloxy-3-methyl-2H-chromen-2-one
pIC50 for MAO-A: 5.26
7-benzylsulfonyl-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-A: 4.73
7-benzylthio-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-A: 5.0
Acetylcholine
competitively inhibits monoamine oxidase A in the brain in a tissue-dependent manner, inhibition of MAO-A in cerebellum
benzoic acid (2H-2-oxochromen-7-yl)methyl ester
pIC50 for MAO-A: 5.02
Clorgyline
D-amphetamine
reversible inhibitor
dehydroepiandrosterone
at 0.1 mM, inhibition of MAO-A by 44.2%
Harmaline
the ability of harmaline to modify the behavioral effects of 5-methoxy-N,N-dimethyltryptamine is mediated by the inhibition of MAOA. Serotonin2A receptors are responsible for the late hyperactivity induced by 5-methoxy-N,N-dimethyltryptamine in the presence of MAOA inhibitors
isatin
moclobemide
N,N'-(1R,2S)-cyclohexane-1,2-diylbis(2-oxo-2H-chromene-3-carboxamide)
-
N,N'-1,2-phenylenebis(2-oxo-2H-chromene-3-carboxamide)
-
N,N'-1,4-phenylenebis(2-oxo-2H-chromene-3-carboxamide)
-
N,N'-butane-1,4-diylbis(2-oxo-2H-chromene-3-carboxamide)
potent inhibitor of MAO-A with high selectivity towards MAO-B
N,N'-butane-1,4-diylbis(7-methoxy-2-oxo-2H-chromene-3-carboxamide)
-
N,N'-ethane-1,2-diylbis(2-oxo-2H-chromene-3-carboxamide)
-
N,N'-hexane-1,6-diylbis(2-oxo-2H-chromene-3-carboxamide)
potent inhibitor of MAO-A with high selectivity towards MAO-B
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
-
N-(2-morpholinoethyl)nicotinamide
-
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3,4-dimethyl-2H-2-oxochromen-7-yl)-N,4-dimethylbenzensulfonamide
pIC50 for MAO-A: 5.34
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
NTZ-1441
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
-
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
NTZ-1442
N-(3-morpholinopropyl)nicotinamide
-
N-(4-benzyloxybenzyl)-4-methylthioamphetamine
-
N-(4-butoxybenzyl)-4-methylthioamphetamine
-
N-(4-hydroxybenzyl)-4-methylthioamphetamine
weak inhibition of MAO-A
N-(4-methoxybenzyl)-4-methylthioamphetamine
-
N-benzyl-(4-methylthioamphetamine)
weak inhibition of MAO-A
N-benzyl-(6-butoxy-2-naphthyl)-2-aminopropane
-
N-benzyl-(6-methoxy-2-naphthyl)-2-aminopropane
-
N-cyclopropyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-cyclopropyl-3-(4-fluorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-cyclopropyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-cyclopropyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-phenyl-1H-indazole-5-carboxamide
-
naringenin
the content of naringenin in Mentha aquatica might explain its use in traditional medicine for depression-like conditions
Pargyline
ParSL
a pargyline based nitroxide spin labeled irreversible inhibitor, active site binding, structure, overview
phenelzine sulfate
mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal
pheniprazine
i.e. (1-methyl-2-phenylethyl)hydrazine. As a reversible inhibitor it is selective towards rat liver MAO-A but the rate of irreversible inhibition of that enzyme is considerably slower
phentermine
rasagiline
tert-butyl (2-[[2-(cyclohexylamino)-1-(3-hydroxyphenyl)-2-oxoethyl](phenyl)amino]-2-oxoethyl)carbamate
non-selective
tranylcypromine hydrochloride
mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal
[4-(benzyloxy)phenoxy]hydrazine
0.1 mM, 43% inhibition
(-)-L-deprenyl
-
-
(2E)-2-[6-[(3-chlorobenzyl)oxy]-1-benzofuran-3(2H)-ylidene]-N-methylacetamide
-
-
(2R)-1-(3-methoxyphenoxy)-3-(1-methylhydrazino)propan-2-ol
-
-
(2S)-1-(3-methoxyphenoxy)-3-(1-methylhydrazino)propan-2-ol
-
-
(2S)-amphetamine
-
-
(3E)-3-[2-(ethylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
1% inhibition of isoform MAO-B at 0.01 mM, 14% inhibition of isoform MAO-A at 0.01 mM
(3E)-3-[2-(isopropylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
4% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3,3,3-trifluoropropane-1-sulfonate
-
5% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-cyanobenzenesulfonate
-
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-fluorobenzenesulfonate
-
6% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-(methylsulfonyl)benzenesulfonate
-
6%inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-acetylbenzenesulfonate
-
13% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-chlorobenzenesulfonate
-
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-cyanobenzenesulfonate
-
6% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-methoxybenzenesulfonate
-
5% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-nitrobenzenesulfonate
-
10% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 5-chlorothiophene-2-sulfonate
-
2% inhibition of isoform MAO-B at 0.01 mM
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl benzenesulfonate
-
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3,3,3-trifluoropropane-1-sulfonate
-
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-cyanobenzenesulfonate
-
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-methoxybenzenesulfonate
-
17% inhibition of isoform MAO-B at 0.01 mM
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl benzenesulfonate
-
6% inhibition of isoform MAO-B at 0.01 mM
(6-benzyloxy-2-naphthyl)-2-aminopropane
-
(6-butoxy-2-naphthyl)-2-aminopropane
-
(6-ethoxy-2-naphthyl)-2-aminopropane
-
(6-methoxy-2-naphthyl)-2-aminopropane
-
(6-methylthio-2-naphthyl)isopropylamine
-
(6-propoxy-2-naphthyl)-2-aminopropane
-
(7-benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile
-
-
(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetonitrile
-
-
(E)-2-(4-fluorophenethyl)-3-fluoroallylamine
-
-
(R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine
-
specific inhibitor of isoform MAO-B
1,4-diphenyl-2-butene
monoamine oxidase B
1-(1-methylhydrazino)-3-(phenylthio)propan-2-ol
-
-
1-(1-methylhydrazino)-3-[methyl(phenyl)amino]propan-2-ol
-
-
1-(1-naphthyl)-2-aminopropane
-
1-(2-naphthyl)-2-aminopropane
-
1-(3,5-diethoxypyridin-4-yl)methanamine dihydrochloride
-
1-(4-benzyloxyphenyl)-2-aminopropane
-
1-(4-butoxyphenyl)-2-aminopropane
-
1-(4-ethoxyphenyl)-2-aminopropane
-
1-(4-methoxy-phenyl)-2-aminopropane
-
1-(4-methylthiophenyl)-2-aminopropane
-
1-(4-propoxyphenyl)-2-aminopropane
-
1-(benzylideneamino)-3,4-dihydroquinolin-2(1H)-one
selective for MAO-B
1-amino-3,4-dihydroquinolin-2(1H)-one
selective for MAO-B
1-N-allylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-B
1-N-allylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor
1-N-ethylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-B
1-N-ethylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor
1-N-methylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-B
1-N-methylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor
1-N-phenylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
selective for MAO-B
1-N-phenylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
non-selective inhibitor
1-phenyl-2-aminopropane
-
1-[3,5-bis(ethylsulfanyl)pyridin-4-yl]methanamine dihydrochloride
-
1-[3,5-bis(tert-butylsulfanyl)pyridin-4-yl]methanamine dihydrochloride
-
1-[3-(4-chlorophenoxy)-2-methoxypropyl]-1-methylhydrazine
-
-
1-[3-(benzyloxy)-5-ethoxypyridin-4-yl]methanamine dihydrochloride
-
11H-indolo[3,2-c]cinnoline
29% inhibition at 0.05 mM
2,2-dibutyl-3-acetyl-5-(3,5-dimethylphenyl)-1,3,4-oxadiazoline
-
0.8 mM, 42.8% inhibition
2,2-dibutyl-5-(2,4-dichlorophenyl)-N-(2,3,5-trifluoro-4-methoxybenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 82% inhibition
2,2-dibutyl-5-(2,4-dichlorophenyl)-N-(2,6-difluorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamid
-
1 mM, 72% inhibition
2,2-dibutyl-5-(4-chlorophenyl)-N-(2,6-difluorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 59% inhibition
2,2-dibutyl-N-(2,6-difluorobenzoyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 69% inhibition
2,2-dibutyl-N-(2,6-difluorobenzoyl)-5-(3,5-dimethylphenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 69% inhibition
2,2-dibutyl-N-(2,6-difluorobenzoyl)-5-(furan-2-yl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 75% inhibition
2,2-dibutyl-N-(2-chlorobenzoyl)-5-(2,4-dichlorophenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 78% inhibition
2,2-dibutyl-N-(2-chlorobenzoyl)-5-(3,5-dimethylphenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 73% inhibition
2-(3-nitrophenyl)-9H-indeno[2,1-d]pyrimidin-9-one
12% inhibition at 0.001 mM
2-(4'-benzyloxyphenyl)thiomorpholin-5-one
-
-
2-(4'-benzyloxyphenyl)thiomorpholine oxalate
-
-
2-(4'-butoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-butoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-ethoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-ethoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-methoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-methoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-propoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-propoxyphenyl)thiomorpholine oxalate
-
-
2-(4-chlorophenyl)-N-cyclohexyl-2-(3-ethynyl-2-oxo-4-phenylquinolin-1(2H)-yl)acetamide
selective for MAO-B
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N,N-dimethylacetamide
-
-
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N-methylacetamide
-
-
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
2-(7-[(3-fluorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
2-(7-[(3-fluorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)propanamide
-
-
2-(7-[(3-hydroxybenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
2-ethylaminobenzylamine dihydrochloride
-
2-methyl-9H-indeno[2,1-d]pyrimidin-9-one
-
2-methylaminobenzylamine dihydrochloride
-
2-phenyl-2H-indeno[1,2-c]pyridazine-3,5-dione
-
2-phenyl-5H-indeno[1,2-d]pyrimidine
37% inhibition at 0.02 mM
2-phenyl-9H-indeno[2,1-d]pyrimidine
-
2-phenylthiomorpholin-5-one
-
-
2-phenylthiomorpholine oxalate
-
-
2-[2-oxo-7-(pyridin-3-ylmethoxy)-2H-chromen-4-yl]acetamide
-
-
2-[2-oxo-7-(pyridin-4-ylmethoxy)-2H-chromen-4-yl]acetamide
-
-
2-[6-[(3-chlorobenzyl)oxy]-1-benzofuran-3-yl]-N-methylacetamide
-
-
2-[7-(3-chlorobenzyloxy)-2-oxo-2H-chromen-4-yl]acetohydrazide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]-N,N-dimethylacetamide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]-N-methylacetamide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]acetohydrazide
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]propanamide
-
-
3,3'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dipropan-1-ol dihydrochloride
-
3,4-dimethyl-7-(2-phenoxyethoxy)-2H-chromen-2-one
pIC50 for MAO-B: 7.57
3,4-dimethyl-7-(2-phenylethyl)-2H-chromen-2-one
pIC50 for MAO-B: 6.34
3,4-dimethyl-7-phenoxy-2H-chromen-2-one
pIC50 for MAO-B: 5.49
3-(1-piperidinyl)-4-aminomethylpyridine dihydrochloride hemihydrate
-
3-(2-furyl)-2-(N-allylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-furyl)-2-(N-ethylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-furyl)-2-(N-methylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-furyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-furyl)-2-thiocarbamoyl-2,3,4,5,6,7-hexahydro-1H-indazol
-
-
3-(2-thienyl)-2-(N-allylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-thienyl)-2-(N-ethylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-thienyl)-2-(N-methylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
3-(2-thienyl)-2-thiocarbamoyl-2,3,4,5,6,7-hexahydro-1H-indazol
-
-
3-(3-aminophenyl)-9H-indeno[1,2-e][1,2,4]triazin-9-one
17% inhibition at 0.01 mM
3-(3-nitrophenyl)-5H-indeno[2,1-e][1,2,4]triazin-5-one
-
3-(3-nitrophenyl)-9H-indeno[1,2-e][1,2,4]triazin-9-one
-
3-(4-fluorophenyl)-5-(2-naphthyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-acetylaminophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-5-(4-methylphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N,5-diphenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N-methyl-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N-methyl-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(4-fluorophenyl)-N-methyl-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
3-(benzyloxy)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(phenoxymethyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-amino-4-aminomethylpyridine dihydrochloride
-
3-cycloheptylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclohexylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclohexylmethylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
3-cyclopentylamino-4-aminomethylpyridine dihydrochloride hemihydrate
-
3-cyclopropylamino-4-aminomethylpyridine dihydrochloride sesquihydrate
-
3-ethylamino-4-aminomethylpyridine dihydrochloride
-
3-methylamino-4-aminomethylpyridine dihydrochloride
-
3-oxo-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
-
3-phenyl-4-(phenylseleno)isoquinoline
reversibly inhibits isoform MAO-B activity
3-phenyl-4-(phenylthio)isoquinoline
-
3-phenyl-9H-indeno[1,2-e][1,2,4]triazin-9-one
-
3-[(1-methylethyl)amino]-4-aminomethylpyridine dihydrochloride
-
3-[(4-fluorophenoxy)methyl]-5H-indeno[1,2-c]pyridazin-5-one
-
3-[2-(ethylamino)-2-oxoethyl]-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
17% inhibition of isoform MAO-A at 0.01 mM
3-[2-(methylamino)-2-oxoethyl]-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
31% inhibition of isoform MAO-A at 0.01 mM
3-[[4-(trifluoromethyl)phenoxy]methyl]-5H-indeno[1,2-c]pyridazin-5-one
48% inhibition at 0.01 mM
4,4'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dibutan-1-ol dihydrochloride
-
4-(2-aminoethyl)-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
-
-
4-(4-fluorophenylseleno)-3-phenylisoquinoline
-
4-(aminomethyl)-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
-
4-(aminomethyl)-7-(benzyloxy)-2H-chromen-2-one
-
-
4-(aminomethyl)-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
-
-
4-(aminomethyl)-N,N'-dibutylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N,N'-diethylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N,N'-dimethylpyridine-3,5-diamine dihydrochloride
-
4-(aminomethyl)-N-methylpyridine-3,5-diamine dihydrochloride
-
4-([benzyl(methyl)amino]methyl)-7-[(3-chlorobenzyl)oxy]-2Hchromen-2-one
-
-
4-Cyanophenol
-
-
4-phenyl-5H-indeno[1,2-d]pyrimidin-5-one
-
4-[(benzylamino)methyl]-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
-
-
4-[(dimethylamino)methyl]-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one
-
-
4-[(ethylamino)methyl]-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one methanesulfonate
-
-
4-[(methylamino)carbonyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
9% inhibition of isoform MAO-B at 0.01 mM, 8% inhibition of isoform MAO-A at 0.01 mM
4-[(methylamino)methyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
-
4-[1-(cyclopropylcarbamothioyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
-
4-[1-(ethylcarbamothioyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
-
4-[2-(methylamino)-2-oxoethyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
-
4-[3-(4-fluorophenyl)-1-(methylcarbamothioyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
-
5-(4-bromophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-bromophenyl)-3-(4-fluorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-bromophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-bromophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(4-chlorophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
5-(benzo[d][1,3]dioxol-5-yl)-2,2-dibutyl-N-(2,6-difluorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 78% inhibition
5-(benzo[d][1,3]dioxol-5-yl)-2,2-dibutyl-N-(2-chlorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 75% inhibition
6,11-dihydro-5H-benzo[a]carbazole
38% inhibition at 0.025 mM
7-(1,3-benzodioxol-5-ylmethoxy)-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
7-(2-hydroxy-2-phenylethyloxy)-3,4-dimethyl-2H-chromen-2-one
-
7-(3-chlorobenzyloxy)-3-methyl-2H-chromen-2-one
pIC50 for MAO-B: 8.29
7-(3-phenylprop-2-en-1-yloxy)-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-B: 6.95
7-(benzenesulfonylmethoxy)-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-B: 6.06
7-(benzyloxy)-4-[(dimethylamino)methyl]-2H-chromen-2-one
-
-
7-(benzyloxy)-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
7-(benzyloxy)-4-[2-(dimethylamino)ethyl]-2H-chromen-2-one
-
-
7-benzenesulfonyloxy-2H-chromen-2-one
pIC50 for MAO-B: 4.26
7-benzyloxy-3-methyl-2H-chromen-2-one
pIC50 for MAO-B: 8.18
7-benzylsulfonyl-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-B: 5.56
7-benzylthio-3,4-dimethyl-2H-chromen-2-one
pIC50 for MAO-B: 7.4
7-[(3-chlorobenzyl)oxy]-4-(chloromethyl)-2H-chromen-2-one
-
-
7-[(3-chlorobenzyl)oxy]-4-[(dimethylamino)methyl]-2H-chromen-2-one
-
-
7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate
-
-
7-[(3-chlorobenzyl)oxy]-4-[2-(methylamino)ethyl]-2H-chromen-2-one
-
-
7-[(3-fluorobenzyl)oxy]-4-[(isopropylamino)methyl]-2H-chromen-2-one methanesulfonate
-
-
7-[(3-fluorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
7-[(3-fluorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate
-
-
8-(-3-chlorostyryl)-caffeine
by means of its dual action as A2A antagonist and MAO-B inhibitor 8-(-3-chlorostyryl)-caffeine reverses behavior and biochemical alterations, observed in the 6-OHDA-lesioned rats, pointing out to its potential benefit for the treatment of Parkinson's disease
8-(3-chlorostyryl)caffeine
monoamine oxidase B
Acetylcholine
competitively inhibits monoamine oxidase B in the brain in a tissue-dependent manner, inhibition of MAO-B in basal ganglia
acridine
-
derivatives, irrevrsible inhibition, sensitivity of isozymes, overview
aminoguanidine
-
complete impairment of SSAO activity produced by aminoguanidine-treatment in obese rats is likely responsible for a weak limitation of fat deposition. Aminoguanidine may be useful for treating obesity via its SSAO blocking properties
benzoic acid (2H-2-oxochromen-7-yl)methyl ester
pIC50 for MAO-B: 5.62
benzyl cyanide
-
reversible inhibitor
beta-phenylethylidenehydrazine
chlorgyline
cis-3-(2-thienyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
Clorgyline
D-amphetamine
reversible inhibitor
dehydroepiandrosterone
at 0.1 mM, inhibition of MAO-B by 61.2%
Deprenyl
fumarate
-
-
Harmane
-
reversible enzyme-specific inhibitor
Iproniazid
-
nonselective inhibitor
iproniazid phosphate
-
-
isatin
reversible inhibitor
ladostigil
-
nonselective inhibitor
lazabemide
-
-
Mesobuthus gibbosus venom peptide
-
with specific MAO-A inhibitory activity, reversible, non-competitive, may be responsible for the anxiogenic effects of the scorpion venom on animals and humans
-
methylene blue
-
reversible enzyme-specific inhibitor
moclobemide
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
-
N-(2-aminoethyl)-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3,4-dimethyl-2H-2-oxochromen-7-yl)-N,4-dimethylbenzensulfonamide
pIC50 for MAO-B: 4.5
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
NTZ-1441
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
-
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
NTZ-1442
N-(4-hydroxybenzyl)-4-methylthioamphetamine
weak inhibition of MAO-B
N-benzyl-(4-methylthioamphetamine)
weak inhibition of MAO-B
N-benzyl-(6-butoxy-2-naphthyl)-2-aminopropane
-
N-benzyl-(6-methoxy-2-naphthyl)-2-aminopropane
-
N-benzyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-acetamide
-
-
N-butyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-acetamide
-
-
N-butyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N-methylacetamide
-
-
N-cyclopropyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-cyclopropyl-3-(4-fluorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-cyclopropyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-cyclopropyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-ethyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
N-phenyl-1H-indazole-5-carboxamide
-
naringenin
the content of naringenin in Mentha aquatica might explain its use in traditional medicine for depression-like conditions
NW 1772
-
specific inhibitor of isoform MAO-B
Pargyline
ParSL
a pargyline based nitroxide spin labeled irreversible inhibitor, active site binding, structure, overview
Phenelzine
phenelzine sulfate
mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal
pheniprazine
i.e. (1-methyl-2-phenylethyl)hydrazine. Mechanism-based MAO inhibitor
phentermine
reversible inhibitor
Phenylethylhydrazine
-
-
pirlindole mesylate
-
reversible enzyme-specific inhibitor
rasagiline
Ro 41-1049
-
potent
safinamide
reversible inhibitor of isoform MAO-B
selegiline
selegilline
-
specific inhibitor of isoform MAO-B
succinate
-
-
tert-butyl (2-[[2-(cyclohexylamino)-1-(3-hydroxyphenyl)-2-oxoethyl](phenyl)amino]-2-oxoethyl)carbamate
non-selective
tert-butyl (2-[[2-(cyclohexylamino)-1-(3-hydroxyphenyl)-2-oxoethyl][2-(phenylcarbonyl)phenyl]amino]-2-oxoethyl)carbamate
selective for MAO-B
tetrindole mesylate
-
reversible enzyme-specific inhibitor
trans-3-(2-thienyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
tranylcypromine
tranylcypromine hydrochloride
mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal
ZnSO4
-
1 mM, about 20% inhibition, monoamine oxidase A
[(E)-N-(2-propynyl)-2-(phenyl)ethylidene]-hydrazine
synthesis and inhibition of MAO isozymes, overview
[(E)-N-bis-(2-propynyl)-2-(phenyl)ethyidene]hydrazine
synthesis and inhibition of MAO isozymes, overview
[(Z)-N-(2-propynyl)-2-(phenyl)ethylidene]-hydrazine
synthesis and inhibition of MAO isozymes, overview
[Cu(2-[4-[bis(4-fluorophenyl)methyl]pipera-zin-1-yl]acetic acid)2(H2O)]
the complex 1 is a potent MAO-B inhibitor
-
additional information
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.21 - 1.04
benzylamine
0.09 - 0.13
kynuramine
0.0215
p-tyramine
monoamine oxidase A
0.35 - 1.48
Phenylethylamine
0.3
serotonin
0.034
1-(4-bromophenyl)methanamine
-
at pH 7.5 and 25°C
0.054
1-(4-chlorophenyl)methanamine
-
at pH 7.5 and 25°C
0.174
1-(4-fluorophenyl)methanamine
-
at pH 7.5 and 25°C
0.08
1-(4-methoxyphenyl)methanamine
-
at pH 7.5 and 25°C
0.055
1-(4-methylphenyl)methanamine
-
at pH 7.5 and 25°C
0.194
1-[4-(trifluoromethyl)phenyl]methanamine
-
at pH 7.5 and 25°C
0.0208 - 1.98
2-Phenylethylamine
0.475
4-hydroxy-3-methoxy-2-phenylethylamine
-
-
0.0238
4-methoxy-2-phenylethylamine
-
-
0.187
5-hydroxytryptamine
-
-
0.0159
5-methoxytryptamine
-
-
0.087 - 1.42
benzylamine
0.405
dopamine
-
-
0.09
kynuramine
isoform MAO A, in 50 mM potassium phosphate assay buffer (pH 7.5), at 25°C
0.0093 - 0.17
O2
0.02031 - 0.061
p-tyramine
0.022
Phenylethylamine
-
-
0.3 - 0.95
serotonin
0.0185 - 3.1
tryptamine
0.02 - 4.6
tyramine
additional information
additional information
-
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.042 - 0.325
benzylamine
0.26 - 2.485
kynuramine
0.897 - 1.42
Phenylethylamine
2.9 - 5.98
serotonin
1.03 - 2.85
1-(4-bromophenyl)methanamine
0.73 - 2
1-(4-chlorophenyl)methanamine
0.23 - 0.98
1-(4-fluorophenyl)methanamine
0.15 - 0.45
1-(4-methoxyphenyl)methanamine
0.27 - 0.8
1-(4-methylphenyl)methanamine
5.57 - 13.52
1-[4-(trifluoromethyl)phenyl]methanamine
0.033 - 2
2-Phenylethylamine
0.325 - 8.3
benzylamine
2.48
kynuramine
isoform MAO A, in 50 mM potassium phosphate assay buffer (pH 7.5), at 25°C
0.17 - 10.67
serotonin
0.066 - 3.5
tryptamine
0.33 - 6.83
tyramine
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1.55
benzylamine
pH 7.5, 25°C, MAO-A
27.61
kynuramine
pH 7.5, 25°C, MAO-A
4.05
Phenylethylamine
pH 7.5, 25°C, MAO-A
19.93
serotonin
pH 7.5, 25°C, MAO-A
326
1-(4-bromophenyl)methanamine
-
at pH 9.0 and 25°C
223
1-(4-chlorophenyl)methanamine
-
at pH 9.0 and 25°C
38
1-(4-fluorophenyl)methanamine
-
at pH 9.0 and 25°C
100
1-(4-methoxyphenyl)methanamine
-
at pH 9.0 and 25°C
347
1-(4-methylphenyl)methanamine
-
at pH 9.0 and 25°C
381
1-[4-(trifluoromethyl)phenyl]methanamine
-
at pH 9.0 and 25°C
4.05
2-Phenylethylamine
isoform MAO A, in 50 mM potassium phosphate assay buffer (pH 7.5), at 25°C
1.55 - 13
benzylamine
27.61
kynuramine
isoform MAO A, in 50 mM potassium phosphate assay buffer (pH 7.5), at 25°C
19.93
serotonin
isoform MAO A, in 50 mM potassium phosphate assay buffer (pH 7.5), at 25°C
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00378
(6-benzyloxy-2-naphthyl)-2-aminopropane
MAO-A
0.00153
(6-butoxy-2-naphthyl)-2-aminopropane
MAO-A
0.00045
(6-ethoxy-2-naphthyl)-2-aminopropane
MAO-A
0.00018
(6-methoxy-2-naphthyl)-2-aminopropane
MAO-A
0.0005
(6-methylthio-2-naphthyl)isopropylamine
MAO-A
0.00068
(6-propoxy-2-naphthyl)-2-aminopropane
MAO-A
0.0056
1-(1-naphthyl)-2-aminopropane
MAO-A
0.00042
1-(2-naphthyl)-2-aminopropane
MAO-A
0.00342
1-(4-benzyloxyphenyl)-2-aminopropane
MAO-A
0.00032
1-(4-butoxyphenyl)-2-aminopropane
MAO-A
0.00022
1-(4-ethoxyphenyl)-2-aminopropane
MAO-A
0.00025
1-(4-methoxy-phenyl)-2-aminopropane
MAO-A
0.00025
1-(4-methylthiophenyl)-2-aminopropane
MAO-A
0.00013
1-(4-propoxyphenyl)-2-aminopropane
MAO-A
0.0333
1-N-allylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
pH 7.6, 37°C, selective for MAO-A, no preincubation
0.0269
1-N-ethylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
pH 7.6, 37°C, selective for MAO-A, no preincubation
0.013
1-N-methylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
pH 7.6, 37°C, selective for MAO-A, no preincubation
0.0608
1-N-phenylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
pH 7.6, 37°C, selective for MAO-A, no preincubation
0.0122
1-phenyl-2-aminopropane
MAO-A
0.006
D-amphetamine
pH 7.5, 25°C, MAO-A
0.0105
isatin
0.151
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
pH 7.5
0.1
N-(4-benzyloxybenzyl)-4-methylthioamphetamine
MAO-A
0.009
N-(4-butoxybenzyl)-4-methylthioamphetamine
MAO-A
0.1
N-(4-hydroxybenzyl)-4-methylthioamphetamine
-
0.1
N-(4-methoxybenzyl)-4-methylthioamphetamine
MAO-A
0.1
N-benzyl-(4-methylthioamphetamine)
-
0.0145
N-benzyl-(6-butoxy-2-naphthyl)-2-aminopropane
MAO-A
0.00693
N-benzyl-(6-methoxy-2-naphthyl)-2-aminopropane
MAO-A
0.00004 - 0.00042
pheniprazine
0.626
phentermine
0.0256
rasagiline
-
0.0122 - 0.1
(2S)-amphetamine
0.00256
(6-benzyloxy-2-naphthyl)-2-aminopropane
MAO-B
0.0163
(6-ethoxy-2-naphthyl)-2-aminopropane
MAO-B
0.1
(6-methoxy-2-naphthyl)-2-aminopropane
MAO-B
0.0136
(6-propoxy-2-naphthyl)-2-aminopropane
MAO-B
0.006
1,4-diphenyl-2-butene
monoamine oxidase B
0.1
1-(1-naphthyl)-2-aminopropane
MAO-B
0.1
1-(2-naphthyl)-2-aminopropane
MAO-B
0.00071
1-(4-benzyloxyphenyl)-2-aminopropane
MAO-B
0.1
1-(4-butoxyphenyl)-2-aminopropane
above, MAO-B
0.1
1-(4-ethoxyphenyl)-2-aminopropane
above, MAO-B
0.1
1-(4-propoxyphenyl)-2-aminopropane
above, MAO-B
0.0337
1-N-allylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
pH 7.6, 37°C, MAO-B, selective for MAO-B
0.024
1-N-ethylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
pH 7.6, 37°C, MAO-B, selective for MAO-B
0.0125
1-N-methylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
pH 7.6, 37°C, selective for MAO-B
0.0371
1-N-phenylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
pH 7.6, 37°C, MAO-B, selective for MAO-B
0.000074 - 0.0275
2-(4'-benzyloxyphenyl)thiomorpholin-5-one
0.00013 - 0.019
2-(4'-benzyloxyphenyl)thiomorpholine oxalate
0.00016 - 0.0509
2-(4'-butoxyphenyl)thiomorpholin-5-one
0.00027 - 0.0141
2-(4'-butoxyphenyl)thiomorpholine oxalate
0.0034 - 0.0123
2-(4'-ethoxyphenyl)thiomorpholin-5-one
0.0022
2-(4'-ethoxyphenyl)thiomorpholine oxalate
0.00928 - 0.0136
2-(4'-methoxyphenyl)thiomorpholin-5-one
0.0039 - 0.0064
2-(4'-methoxyphenyl)thiomorpholine oxalate
0.0015 - 0.0087
2-(4'-propoxyphenyl)thiomorpholin-5-one
0.00098 - 0.0037
2-(4'-propoxyphenyl)thiomorpholine oxalate
0.00919 - 0.0096
2-phenylthiomorpholin-5-one
0.0022 - 0.0106
2-phenylthiomorpholine oxalate
0.0011
8-(3-chlorostyryl)caffeine
monoamine oxidase B
6
D-amphetamine
isoform MAO A, in 50 mM potassium phosphate assay buffer (pH 7.5), at 25°C
0.00075
Harmane
-
at pH 7.5 and 25°C
10
isatin
isoform MAO A, in 50 mM potassium phosphate assay buffer (pH 7.5), at 25°C
0.000026
methylene blue
-
at pH 7.5 and 25°C
0.107
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
pH 7.5
0.1
N-(4-hydroxybenzyl)-4-methylthioamphetamine
-
0.1
N-benzyl-(4-methylthioamphetamine)
-
0.0222
N-benzyl-(6-butoxy-2-naphthyl)-2-aminopropane
MAO-B
0.0247
N-benzyl-(6-methoxy-2-naphthyl)-2-aminopropane
MAO-B
0.0053
Pargyline
-
0.00075 - 0.00245
pheniprazine
625
phentermine
isoform MAO A, in 50 mM potassium phosphate assay buffer (pH 7.5), at 25°C
0.023
Phenylethylhydrazine
-
-
0.00077
pirlindole mesylate
-
at pH 7.5 and 25°C
0.0036
tetrindole mesylate
-
at pH 7.5 and 25°C
additional information
additional information
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0679
1-N-allylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, selective for MAO-A, no preincubation
0.366
1-N-allylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, MAO-A, non-selective inhibitor, no preincubation
0.0445
1-N-ethylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, selective for MAO-A, no preincubation
0.33
1-N-ethylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, MAO-A, non-selective inhibitor, no preincubation
0.03
1-N-methylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, selective for MAO-A, no preincubation
0.302
1-N-methylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, MAO-A, non-selective inhibitor, no preincubation
0.098
1-N-phenylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, selective for MAO-A, no preincubation
0.326
1-N-phenylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, MAO-A, non-selective inhibitor, no preincubation
0.402 - 0.49
1-thiocarbamoyl-3-(4-bromophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
0.2853 - 0.51
1-thiocarbamoyl-3-(4-bromophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
0.0342 - 0.51
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
0.0382 - 0.5
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
0.00496 - 0.485
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
0.0067 - 0.53
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
0.0638 - 0.513
1-thiocarbamoyl-3-(4-methylphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
0.0523 - 0.501
1-thiocarbamoyl-3-(4-methylphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
0.63
1-[3-(benzyloxy)-5-ethoxypyridin-4-yl]methanamine dihydrochloride
Rattus norvegicus
-
0.0297
11H-indolo[3,2-c]cinnoline
Rattus norvegicus
pH 7.4, 37°C
0.00032 - 0.0085
2-bromo-N-(2-morpholinoethyl)nicotinamide
0.0019 - 0.035
2-bromo-N-(3-morpholinopropyl)nicotinamide
0.028 - 0.1
2-chloro-6-methyl-N-(2-morpholinoethyl)nicotinamide
0.1
2-chloro-6-methyl-N-(3-morpholinopropyl)nicotinamide
0.0018 - 0.0026
2-chloro-N-(2-morpholinoethyl)nicotinamide
0.0065 - 0.0094
2-chloro-N-(3-morpholinopropyl)nicotinamide
0.045 - 0.1
2-hydroxy-N-(2-morpholinoethyl)nicotinamide
0.1
2-hydroxy-N-(3-morpholinopropyl)nicotinamide
0.0471
2-methyl-9H-indeno[2,1-d]pyrimidin-9-one
Rattus norvegicus
pH 7.4, 37°C
0.018
2-phenyl-5H-indeno[1,2-d]pyrimidine
Rattus norvegicus
pH 7.4, 37°C
0.0167
2-phenyl-9H-indeno[2,1-d]pyrimidine
Rattus norvegicus
pH 7.4, 37°C
0.4874
3-(4-fluorophenyl)-5-(2-naphthyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.19356
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.05522
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.20534
3-(4-fluorophenyl)-N-methyl-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.47019
3-(4-fluorophenyl)-N-methyl-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.06128
3-(4-fluorophenyl)-N-methyl-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.15
3-cycloheptylamino-4-aminomethylpyridine dihydrochloride monohydrate
Rattus norvegicus
-
0.095
3-cyclohexylmethylamino-4-aminomethylpyridine dihydrochloride monohydrate
Rattus norvegicus
-
0.43
3-ethylamino-4-aminomethylpyridine dihydrochloride
Rattus norvegicus
-
0.42
3-methylamino-4-aminomethylpyridine dihydrochloride
Rattus norvegicus
-
2.2
3-[(1-methylethyl)amino]-4-aminomethylpyridine dihydrochloride
Rattus norvegicus
-
0.0308
4-(4-chlorophenyl)-5H-indeno[1,2-c]pyridazin-5-one
Rattus norvegicus
pH 7.4, 37°C
0.01
4-(aminomethyl)-N,N'-dibutylpyridine-3,5-diamine dihydrochloride
Rattus norvegicus
-
0.063
4-(aminomethyl)-N,N'-diethylpyridine-3,5-diamine dihydrochloride
Rattus norvegicus
-
0.044
4-(aminomethyl)-N,N'-dimethylpyridine-3,5-diamine dihydrochloride
Rattus norvegicus
-
0.17
4-(aminomethyl)-N-methylpyridine-3,5-diamine dihydrochloride
Rattus norvegicus
-
0.00075 - 0.074
4-chloro-N-(2-morpholinoethyl)nicotinamide
0.0075 - 0.053
4-chloro-N-(3-morpholinopropyl)nicotinamide
0.0216
4-phenyl-5H-indeno[1,2-d]pyrimidin-5-one
Rattus norvegicus
pH 7.4, 37°C
0.10077
4-[3-(4-fluorophenyl)-1-(methylcarbamothioyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.000084 - 0.048
5,6-dichloro-N-(2-morpholinoethyl)nicotinamide
0.0001 - 0.045
5,6-dichloro-N-(3-morpholinopropyl)nicotinamide
0.01339
5-(4-bromophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.03044
5-(4-bromophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.0299
5-(4-bromophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.00625
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.03724
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.0199
5-(4-chlorophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.00834
5-(4-chlorophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.026 - 0.055
5-bromo-N-(2-morpholinoethyl)nicotinamide
0.023 - 0.065
5-bromo-N-(3-morpholinopropyl)nicotinamide
0.000045 - 0.026
5-chloro-6-hydroxy-N-(2-morpholinoethyl)nicotinamide
0.012 - 0.082
5-chloro-6-hydroxy-N-(3-morpholinopropyl)nicotinamide
0.012
6,11-dihydro-5H-benzo[a]carbazole
Rattus norvegicus
pH 7.4, 37°C
0.00018 - 0.034
6-chloro-N-(2-morpholinoethyl)nicotinamide
0.00038 - 0.075
6-chloro-N-(3-morpholinopropyl)nicotinamide
0.015 - 0.1
6-fluoro-N-(2-morpholinoethyl)nicotinamide
0.08 - 0.1
6-fluoro-N-(3-morpholinopropyl)nicotinamide
0.00043 - 0.1
6-hydroxy-N-(2-morpholinoethyl)nicotinamide
0.056 - 0.1
6-hydroxy-N-(3-morpholinopropyl)nicotinamide
0.086 - 0.1
6-methyl-N-(2-morpholinoethyl)nicotinamide
0.1
6-methyl-N-(3-morpholinopropyl)nicotinamide
0.0003 - 0.00416
Clorgyline
10.7
moclobemide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.068 - 0.1
N-(2-morpholinoethyl)nicotinamide
0.01
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.00174
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.00188
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
10
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
1.69
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.1
N-(3-morpholinopropyl)nicotinamide
0.2459
N-cyclopropyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.43089
N-cyclopropyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.08991
N-cyclopropyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.19886
N-ethyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.1859
N-ethyl-3-(4-fluorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.47066
N-ethyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.09053
N-ethyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-A, at pH 7.6 and 37°C
0.01
N-phenyl-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.955
naringenin
Rattus norvegicus
-
0.00272 - 0.39
Pargyline
580
safinamide
Rattus norvegicus
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.25
tert-butyl (2-[[2-(cyclohexylamino)-1-(3-hydroxyphenyl)-2-oxoethyl](phenyl)amino]-2-oxoethyl)carbamate
Rattus norvegicus
37°C, no preincubation
0.000036 - 0.0031
(2E)-2-[6-[(3-chlorobenzyl)oxy]-1-benzofuran-3(2H)-ylidene]-N-methylacetamide
0.0042
(3E)-3-[2-(ethylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.0000091
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3,3,3-trifluoropropane-1-sulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000041
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000019
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-cyanobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000041
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-fluorobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000019
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-(methylsulfonyl)benzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000029
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-acetylbenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000012
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-chlorobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000045
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-cyanobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000016
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-methoxybenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000037
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-nitrobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.0000098
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 5-chlorothiophene-2-sulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000034
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl benzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000011
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3,3,3-trifluoropropane-1-sulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000015
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000011
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-cyanobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000007
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-methoxybenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.000024
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl benzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.0002 - 0.00023
(7-benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile
0.000016 - 0.00047
(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetonitrile
0.066
1-(benzylideneamino)-3,4-dihydroquinolin-2(1H)-one
Rattus norvegicus
37°C, no preincubation
0.06
1-amino-3,4-dihydroquinolin-2(1H)-one
Rattus norvegicus
37°C, no preincubation
0.059
1-N-allylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, selective for MAO-B, no preincubation
0.39
1-N-allylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, MAO-B, non-selective inhibitor, no preincubation
0.051
1-N-ethylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, selective for MAO-B, no preincubation
0.38
1-N-ethylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, MAO-B, non-selective inhibitor, no preincubation
0.029
1-N-methylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, selective for MAO-B, no preincubation
0.349
1-N-methylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, MAO-B, non-selective inhibitor, no preincubation
0.066
1-N-phenylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, selective for MAO-B, no preincubation
0.345
1-N-phenylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
Rattus norvegicus
pH 7.6, 37°C, MAO-B, non-selective inhibitor, no preincubation
1
1-[3-(benzyloxy)-5-ethoxypyridin-4-yl]methanamine dihydrochloride
Rattus norvegicus
-
0.063
2-(4-chlorophenyl)-N-cyclohexyl-2-(3-ethynyl-2-oxo-4-phenylquinolin-1(2H)-yl)acetamide
Rattus norvegicus
37°C, no preincubation
0.00004 - 0.1
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N,N-dimethylacetamide
0.000024 - 0.0005
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N-methylacetamide
0.00003 - 0.026
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
0.00005 - 0.07
2-(7-[(3-fluorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
0.002 - 0.1
2-(7-[(3-fluorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)propanamide
0.001 - 0.0043
2-(7-[(3-hydroxybenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
0.0094
2-methyl-9H-indeno[2,1-d]pyrimidin-9-one
Rattus norvegicus
pH 7.4, 37°C
0.038
2-phenyl-2H-indeno[1,2-c]pyridazine-3,5-dione
Rattus norvegicus
pH 7.4, 37°C
0.013
2-phenyl-9H-indeno[2,1-d]pyrimidine
Rattus norvegicus
pH 7.4, 37°C
0.0013 - 0.021
2-[2-oxo-7-(pyridin-3-ylmethoxy)-2H-chromen-4-yl]acetamide
0.002 - 0.0265
2-[2-oxo-7-(pyridin-4-ylmethoxy)-2H-chromen-4-yl]acetamide
0.000284 - 0.001
2-[6-[(3-chlorobenzyl)oxy]-1-benzofuran-3-yl]-N-methylacetamide
0.00009 - 0.0025
2-[7-(3-chlorobenzyloxy)-2-oxo-2H-chromen-4-yl]acetohydrazide
0.0004 - 0.0231
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]-N,N-dimethylacetamide
0.000015 - 0.0028
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]-N-methylacetamide
0.0002 - 0.008
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide
0.00004 - 0.00144
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]acetohydrazide
0.0063 - 0.1
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]propanamide
0.00053 - 0.00358
3-(2-furyl)-2-(N-allylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
0.00273 - 0.0028
3-(2-furyl)-2-(N-ethylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
0.0029 - 0.00318
3-(2-furyl)-2-(N-methylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
0.0088 - 0.0707
3-(2-furyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
0.00127 - 0.00136
3-(2-furyl)-2-thiocarbamoyl-2,3,4,5,6,7-hexahydro-1H-indazol
0.00027 - 0.002
3-(2-thienyl)-2-(N-allylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
0.00042 - 0.0025
3-(2-thienyl)-2-(N-ethylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
0.0017 - 0.0026
3-(2-thienyl)-2-(N-methylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
0.0011 - 0.0021
3-(2-thienyl)-2-thiocarbamoyl-2,3,4,5,6,7-hexahydro-1H-indazol
0.000912
3-(3-nitrophenyl)-5H-indeno[2,1-e][1,2,4]triazin-5-one
Rattus norvegicus
pH 7.4, 37°C
0.00008
3-(3-nitrophenyl)-9H-indeno[1,2-e][1,2,4]triazin-9-one
Rattus norvegicus
pH 7.4, 37°C
0.09856
3-(4-fluorophenyl)-5-(2-naphthyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.25623
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.50045
3-(4-fluorophenyl)-5-(4-methoxyphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.19844
3-(4-fluorophenyl)-N-methyl-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.09045
3-(4-fluorophenyl)-N-methyl-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.47021
3-(4-fluorophenyl)-N-methyl-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.055
3-(benzyloxy)-5H-indeno[1,2-c]pyridazin-5-one
Rattus norvegicus
pH 7.4, 37°C
0.00251
3-(phenoxymethyl)-5H-indeno[1,2-c]pyridazin-5-one
Rattus norvegicus
pH 7.4, 37°C
0.07
3-cyclohexylmethylamino-4-aminomethylpyridine dihydrochloride monohydrate
Rattus norvegicus
-
0.09
3-cyclopropylamino-4-aminomethylpyridine dihydrochloride sesquihydrate
Rattus norvegicus
-
0.03645
3-phenyl-4-(phenylseleno)isoquinoline
Rattus norvegicus
isoform MAO-B, at pH 7.4 and 37°C
0.07586
3-phenyl-4-(phenylthio)isoquinoline
Rattus norvegicus
isoform MAO-B, at pH 7.4 and 37°C
0.00631
3-phenyl-9H-indeno[1,2-e][1,2,4]triazin-9-one
Rattus norvegicus
pH 7.4, 37°C
2
3-[(1-methylethyl)amino]-4-aminomethylpyridine dihydrochloride
Rattus norvegicus
-
0.0019
3-[(4-fluorophenoxy)methyl]-5H-indeno[1,2-c]pyridazin-5-one
Rattus norvegicus
pH 7.4, 37°C
0.000409
3-[2-(methylamino)-2-oxoethyl]-1-benzofuran-6-yl 3-chlorobenzenesulfonate
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.00025 - 0.0318
4-(2-aminoethyl)-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
0.08241
4-(4-fluorophenylseleno)-3-phenylisoquinoline
Rattus norvegicus
isoform MAO-B, at pH 7.4 and 37°C
0.000997 - 0.0033
4-(aminomethyl)-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
0.000021 - 0.0044
4-(aminomethyl)-7-(benzyloxy)-2H-chromen-2-one
0.000015 - 0.002
4-(aminomethyl)-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
0.02
4-(aminomethyl)-N,N'-dibutylpyridine-3,5-diamine dihydrochloride
Rattus norvegicus
-
0.3
4-(aminomethyl)-N,N'-diethylpyridine-3,5-diamine dihydrochloride
Rattus norvegicus
-
0.25
4-(aminomethyl)-N,N'-dimethylpyridine-3,5-diamine dihydrochloride
Rattus norvegicus
-
0.008 - 0.1
4-([benzyl(methyl)amino]methyl)-7-[(3-chlorobenzyl)oxy]-2Hchromen-2-one
0.034
4-phenyl-5H-indeno[1,2-d]pyrimidin-5-one
Rattus norvegicus
pH 7.4, 37°C
0.0036 - 0.1
4-[(benzylamino)methyl]-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
0.00051 - 0.1
4-[(dimethylamino)methyl]-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one
0.0001 - 0.0226
4-[(ethylamino)methyl]-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one methanesulfonate
0.0017 - 0.0054
4-[(methylamino)methyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
0.000111 - 0.0083
4-[2-(methylamino)-2-oxoethyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
0.47045
4-[3-(4-fluorophenyl)-1-(methylcarbamothioyl)-4,5-dihydro-1H-pyrazol-5-yl]-N-methylbenzamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.49622
5-(4-bromophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.47067
5-(4-bromophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.48023
5-(4-bromophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.50023
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.48882
5-(4-chlorophenyl)-3-(4-fluorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.50011
5-(4-chlorophenyl)-N-cyclopropyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.47022
5-(4-chlorophenyl)-N-ethyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.00002 - 0.0054
7-(1,3-benzodioxol-5-ylmethoxy)-4-[(methylamino)methyl]-2H-chromen-2-one
0.0018 - 0.1
7-(benzyloxy)-4-[(dimethylamino)methyl]-2H-chromen-2-one
0.0000128 - 0.0154
7-(benzyloxy)-4-[(methylamino)methyl]-2H-chromen-2-one
0.00046 - 0.026
7-(benzyloxy)-4-[2-(dimethylamino)ethyl]-2H-chromen-2-one
0.000427
7-[(3-chlorobenzyl)oxy]-4-(chloromethyl)-2H-chromen-2-one
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.00112 - 0.0508
7-[(3-chlorobenzyl)oxy]-4-[(dimethylamino)methyl]-2H-chromen-2-one
0.000013 - 0.006
7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one
0.0003 - 0.074
7-[(3-chlorobenzyl)oxy]-4-[2-(methylamino)ethyl]-2H-chromen-2-one
0.0038 - 0.091
7-[(3-fluorobenzyl)oxy]-4-[(isopropylamino)methyl]-2H-chromen-2-one methanesulfonate
0.000018 - 0.0135
7-[(3-fluorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one
0.0312 - 0.0931
cis-3-(2-thienyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
0.105
Deprenyl
Rattus norvegicus
-
0.00047
fumarate
Rattus norvegicus
-
-
0.00759
iproniazid phosphate
Rattus norvegicus
pH and temperature not specified in the publication
-
0.0007
malate
Rattus norvegicus
-
-
0.01
moclobemide
Rattus norvegicus
-
isoform MAO-A, pH and temperature not specified in the publication
0.01 - 0.1
N-(2-aminoethyl)-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
0.00000382
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00000132
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00000143
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.0000225
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00000565
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00000889
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.000221
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.708
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00000236
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00136
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.005 - 0.1
N-benzyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-acetamide
0.01 - 0.1
N-butyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-acetamide
0.01 - 0.1
N-butyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N-methylacetamide
0.26476
N-cyclopropyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.0999
N-cyclopropyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.48055
N-cyclopropyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.19723
N-ethyl-3-(4-fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.1842
N-ethyl-3-(4-fluorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.09821
N-ethyl-3-(4-fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.47004
N-ethyl-3-(4-fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
Rattus norvegicus
isoform MAO-B, at pH 7.6 and 37°C
0.000708
N-phenyl-1H-indazole-5-carboxamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.955
naringenin
Rattus norvegicus
-
0.00405
paragyline
Rattus norvegicus
-
0.018
safinamide
Rattus norvegicus
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00062
succinate
Rattus norvegicus
-
-
0.33
tert-butyl (2-[[2-(cyclohexylamino)-1-(3-hydroxyphenyl)-2-oxoethyl](phenyl)amino]-2-oxoethyl)carbamate
Rattus norvegicus
37°C, no preincubation
0.079
tert-butyl (2-[[2-(cyclohexylamino)-1-(3-hydroxyphenyl)-2-oxoethyl][2-(phenylcarbonyl)phenyl]amino]-2-oxoethyl)carbamate
Rattus norvegicus
37°C, no preincubation
0.0201 - 0.0695
trans-3-(2-thienyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
0.00185
[Cu(2-[4-[bis(4-fluorophenyl)methyl]pipera-zin-1-yl]acetic acid)2(H2O)]
Rattus norvegicus
pH and temperature not specified in the publication
-
additional information
additional information
-
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.00004
substrate histamine, at high substrate concentration
0.00011
substrate tyramine, at low substrate concentration
0.00021
substrate beta-phenylethylamine, at low substrate concentration
0.0003
substrate benzylamine, at low substrate concentration
0.00036
substrate 1-methylhistamine, at high substrate concentration
0.00054
substrate benzylamine, at high substrate concentration
0.00163
substrate beta-phenylethylamine, at high substrate concentration
0.00175
substrate tyramine, at high substrate concentration
0.00316
substrate serotonin, at low substrate concentration
0.0046
substrate serotonin, at high substrate concentration
0.043
substrate p-tyramine, monoamine oxidase A
1.42
purified recombinant MAO-A
0.00009
substrate beta-phenylethylamine, at low substrate concentration
0.00018
substrate tyramine, at low substrate concentration
0.00019
substrate benzylamine, at low substrate concentration
0.00054
substrate histamine, at high substrate concentration
0.00092
substrate beta-phenylethylamine, at high substrate concentration
0.00095
substrate 1-methylhistamine, at high substrate concentration
0.00125
substrate benzylamine, at high substrate concentration
0.00155
substrate tyramine, at high substrate concentration
0.025
cell lysate, in 50 mM potassium phosphate assay buffer (pH 7.5), at 25°C
1.42
after purification, isoform MAO A, in 50 mM potassium phosphate assay buffer (pH 7.5), at 25°C
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7.4
-
assay at
7.5
-
assay at
7.6
-
assay at
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
-
lability increased at pH-values greater than 10
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
25
-
assay at
30
-
assay at
37
-
assay at
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
brown fat of hypothyroid and hyperthyroid rats. Hypothyroidism increases MAO activity. T3 increased content of uncoupling protein 1 decreases activity of MAO
Manually annotated by BRENDA team
additional information
-
predominance of monoamine oxidase A, mRNA for monoamine oxidase B is present but the protein itself is undetected with beta-phenylethylamine as substrate
Manually annotated by BRENDA team
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
physiological function
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION?
AOFA_RAT
526
0
59508
Swiss-Prot
other Location (Reliability: 2)
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
60000
x * 60000, recombinant MAO-A, SDS-PAGE
59230
MALDI-TOF MS
60000
65000
-
x * 65000, SDS-PAGE
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
?
x * 60000, recombinant MAO-A, SDS-PAGE
monomer or dimer
MAOA is partly dimeric in the mitochondrial outer membrane and in octyl beta-D-glucopyranoside micelles
dimer
monomer
additional information
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
flavoprotein
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
hanging drop vapour diffusion method, crystal structure of the enzyme complexed with the specific inhibitor, clorgyline, at 3.2 A resolution
hanging drop vapour-diffusion method at 277K with a reservoir containing 12% w/v polyethylene glycol 2000 monomethylether, 100 mM sodium acetate, 100 mM sodium phosphate buffer, pH 6.2, and 26% v/v glycerol. Enzyme complexed with clorgyline, 3.2 A resolution, crystals belong to the space group P4(3)2(1)2, with unit-cell parameters a = b = 158.2, c = 258.4 A
-
MAO A, X-ray diffraction structure determination at 3.3 A resolution. The dimer structure of rat MAO A is more readily crystallized than its monomeric form
-
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
C406A
-
MAO-A, Km for serotonin and tyramine not altered
Y402A
-
decrease in activity not significant, decrease in the FAD incorporation
Y402F
Y403A
-
the ratio of turnover number to Km-value for serotonin is 95.6fold lower than that of the mutant enzyme, the ratio of turnover number to Km-value for phenylethylamine is 210fold lower than that of the wild-type enzyme, the ratio of turnover number to Km-value for tyramine is 170fold lower than that of the wild-type enzyme, the ratio of turnover number to KM-value for tryptamine is 91fold lower than that of the wild-type enzyme. Mutant enzyme is sensitive to trypsin treatment, while the wild-type enzyme is resistant
Y407A
Y407F
Y410A
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0
stable for at least 120 min without losing activity
0 - 30
isoform MAO A remains fully active when incubated at 0°C for 120 minutes. At 25°C, only 10% of isoform MAO A activity is lost after 120 min incubation. The enzyme retains about 80% catalytic activity after incubation at 30°C for 120 min
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
50% glycerol stabilize the enzyme
wild-type enzyme is resistant to trypsin treatment, mutant enzyms Y403A, Y407A and Y410A are sensitive
-
OXIDATION STABILITY
ORGANISM
UNIPROT
LITERATURE
under certain experimental conditions e.g. preincubation with Cu2+, treatment with oxidized oleic acid reversible qualitative alterations in catalytic properties occur, e.g. decrease in monoamine oxidase activity and appearance of ability to deaminate some nitrogenous compounds such as histamine, putrescine, cadaverine, lysine, AMP
-
394558
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
30°C, 8 h, 30% of initial activity of Ala-mutated enzyme, in the presence of 0.005 mM FAD 70% of activity
-
30°C, 8 h, no decrease in activity of wild-type enzyme
-
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
recombinant MAO-A from Pichia pastoris strain KM71 outer mitochondrial membranes by Triton X-100 solubilization and anion exchange chromatography
DEAE-Sepharose column chromatography
His-tagged rat enzyme and its mutants Y403A, Y402F, Y407A, Y407F, Y410A
-
recombinant enzyme
-
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
expressed in COS-1 cells
expression in Cos-1 cells
expression of MAOA in Pichia pastoris KM71 cell mitochondria
overexpression of MAO-A in Pichia pastoris strain KM71
expressed in COS-1 cells
expressed in Pichia pastoris
expressed in Pichia pastoris. Recombinant rMAOB, overexpressed in Pichia pastoris, is exclusively localized in the outer mitochondrial membrane of the Pichia cells
expression in Cos-1 cells
expression in Esherichia coli, two forms of the enzyme: a catalytically active form exhibits similar properties as rat liver enzyme and an inactive form
-
expression in Saccharomyces cerevisiae BJ 2168
-
expression in Saccharomyces cerevisiae YSA-1C
-
expression in yeast
-
expression of MAOB in Pichia pastoris KM71 cell mitochondria
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
drug development
MAO-A is a target for a series of therapeutically valuable drugs. Thus, selective MAO-A inhibitors are used as antidepressants
medicine
drug development
MAO-B is a target for a series of therapeutically valuable drugs. Thus, selective MAO-B inhibitors are used in the treatment of Parkinson’s disease
medicine
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Balsa, D.; Fernandez-Alverez, E.; Tipton, K.F.; Unzeta, M.
Monoamine oxidase inhibitory potencies and selectivities of 2-[N-(2-propynyl)-aminomethyl]-1-methyl indole derivatives
Biochem. Soc. Trans.
19
215-218
1991
Rattus norvegicus
Manually annotated by BRENDA team
Ma, J.; Ito, A.
Tyrosine residues near the FAD binding site are critical for FAD binding and for the maintenance of the stable and active conformation of rat monoamine oxidase A
J. Biochem.
131
107-111
2002
Rattus norvegicus, Rattus norvegicus MAO-A
Manually annotated by BRENDA team
Veryovkina, L.V.; Samed, M.M.A.; Gorkin, V.Z.
Mitochondrial monoamine oxidase of rat liver: reversible qualitative alterations in catalytic properties
Biochim. Biophys. Acta
258
56-70
1972
Rattus norvegicus
Manually annotated by BRENDA team
Tipton, K.F.; Spires, I.P.C.
The kinetics of phenethylhydrazine oxidation by monoamine oxidase
Biochem. J.
125
521-524
1971
Rattus norvegicus, Sus scrofa
Manually annotated by BRENDA team
Houslay, M.D.; Tipton, K.F.
A kinetic evaluation of monoamine oxidase activity in rat liver mitochondrial outer membranes
Biochem. J.
139
645-652
1974
Rattus norvegicus
Manually annotated by BRENDA team
Dennick, R.G.; Mayer, R.J.
Purification and immunochemical characterization of monoamine oxidase from rat and human liver
Biochem. J.
161
167-174
1977
Homo sapiens, Rattus norvegicus
Manually annotated by BRENDA team
Stadt, M.A.; Banks, P.A.; Kobes, R.D.
Purification of rat liver monoamine oxidase by octyl glucoside extraction and reconstitution
Arch. Biochem. Biophys.
214
223-230
1982
Rattus norvegicus
Manually annotated by BRENDA team
McCauley, R.
Properties of a monoamine oxidase from rat liver mitochondrial outer membranes
Arch. Biochem. Biophys.
189
8-13
1978
Rattus norvegicus
Manually annotated by BRENDA team
Youdim, M.B.H.; Tenne, M.
Assay and purification of liver monoamine oxidase
Methods Enzymol.
142
617-627
1987
Rattus norvegicus
Manually annotated by BRENDA team
Hirashiki, I.; Ogata, F.; Ito, A.
Rat monoamine oxidase B expressed in Escherichia coli has a covalently-bound FAD
Biochem. Mol. Biol. Int.
37
39-44
1995
Rattus norvegicus
Manually annotated by BRENDA team
Hiro, I.; Tsugeno, Y.; Hirashiki, I.; Ogata, F.; Ito, A.
Characterization of rat monoamine oxidase A with noncovalently-bound FAD expressed in yeast cells
J. Biochem.
120
759-765
1996
Rattus norvegicus
Manually annotated by BRENDA team
Ma, J.; Kubota, F.; Yoshimura, M.; Yamashita, E.; Nakagawa, A.; Ito, A.; Tsukihara, T.
Crystallization and preliminary crystallographic analysis of rat monoamine oxidase A complexed with clorgyline
Acta Crystallogr. Sect. D
60
317-319
2004
Rattus norvegicus
Manually annotated by BRENDA team
Ucar, G.
Substrate specificities of monoamine oxidase isoforms
FABAD J. Pharm. Sci.
27
149-156
2002
Homo sapiens, Rattus norvegicus
-
Manually annotated by BRENDA team
Ma, J.; Yoshimura, M.; Yamashita, E.; Nakagawa, A.; Ito, A.; Tsukihara, T.
Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors
J. Mol. Biol.
338
103-114
2004
Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Egashira, T.; Takayama, F.; Sakai, K.
Inhibition by Zn2+ of A-form monoamine oxidase in monkey brain mitochondria
J. Pharm. Sci.
91
239-245
2003
Oryctolagus cuniculus, Macaca fuscata, Rattus norvegicus
Manually annotated by BRENDA team
Guimaraes, J.T.; Vindis, C.; Soares-da-Silva, P.; Parini, A.
Differential substrate specificity of monoamine oxidase in the rat heart and renal cortex
Life Sci.
73
955-967
2003
Rattus norvegicus
Manually annotated by BRENDA team
Ucar, G.; Tas, C.; Tuemer, A.
Monoamine oxidase inhibitory activities of the scorpion Mesobuthus gibbosus (Buthidae) venom peptides
Toxicon
45
43-52
2005
Homo sapiens, Rattus norvegicus
Manually annotated by BRENDA team
Petrovic, N.; Cvijic, G.; Djordjevic, J.; Davidovic, V.
The activities of antioxidant enzymes and monoamine oxidase and uncoupling protein 1 content in brown fat of hypo- and hyperthyroid rats
Ann. N. Y. Acad. Sci.
1040
431-435
2005
Rattus norvegicus
Manually annotated by BRENDA team
Ochiai, Y.; Itoh, K.; Sakurai, E.; Adachi, M.; Tanaka, Y.
Substrate selectivity of monoamine oxidase A, monoamine oxidase B, diamine oxidase, and semicarbazide-sensitive amine oxidase in COS-1 expression systems
Biol. Pharm. Bull.
29
2362-2366
2006
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Hubalek, F.; Binda, C.; Khalil, A.; Li, M.; Mattevi, A.; Castagnoli, N.; Edmondson, D.E.
Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors
J. Biol. Chem.
280
15761-15766
2005
Equus caballus, Ovis aries, Rattus norvegicus (P19643), Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens, Bos taurus (P56560), Bos taurus, Mus musculus (Q8BW75), Mus musculus
Manually annotated by BRENDA team
Dar, A.; Khan, K.M.; Ateeq, H.S.; Khan, S.; Rahat, S.; Perveen, S.; Supuran, C.T.
Inhibition of monoamine oxidase-A activity in rat brain by synthetic hydrazines: structure-activity relationship (SAR)
J. Enzyme Inhib. Med. Chem.
20
269-274
2005
Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Huh, J.W.; Choi, M.M.; Lee, J.H.; Yang, S.J.; Kim, M.J.; Choi, J.; Lee, K.H.; Lee, J.E.; Cho, S.W.
Activation of monoamine oxidase isotypes by prolonged intake of aluminum in rat brain
J. Inorg. Biochem.
99
2088-2091
2005
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Bertini, V.; Buffoni, F.; Ignesti, G.; Picci, N.; Trombino, S.; Iemma, F.; Alfei, S.; Pocci, M.; Lucchesini, F.; De Munno, A.
Alkylamino derivatives of 4-aminomethylpyridine as inhibitors of copper-containing amine oxidases
J. Med. Chem.
48
664-670
2005
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Catto, M.; Nicolotti, O.; Leonetti, F.; Carotti, A.; Favia, A.D.; Soto-Otero, R.; Mendez-Alvarez, E.; Carotti, A.
Structural insights into monoamine oxidase inhibitory potency and selectivity of 7-substituted coumarins from ligand- and target-based approaches
J. Med. Chem.
49
4912-4925
2006
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Palaska, E.; Aydin, F.; Ucar, G.; Erol, D.
Synthesis and monoamine oxidase inhibitory activities of 1-thiocarbamoyl-3,5-diphenyl-4,5-dihydro-1H-pyrazole derivatives
Arch. Pharm.
341
209-215
2008
Rattus norvegicus (P21396), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Upadhyay, A.K.; Wang, J.; Edmondson, D.E.
Comparison of the structural properties of the active site cavities of human and rat monoamine oxidase A and B in their soluble and membrane-bound forms
Biochemistry
47
526-536
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Kumar, P.; Taha, A.; Sharma, D.; Kale, R.K.; Baquer, N.Z.
Effect of dehydroepiandrosterone (DHEA) on monoamine oxidase activity, lipid peroxidation and lipofuscin accumulation in aging rat brain regions
Biogerontology
9
235-246
2008
Rattus norvegicus
Manually annotated by BRENDA team
Guillem, K.; Vouillac, C.; Koob, G.F.; Cador, M.; Stinus, L.
Monoamine oxidase inhibition dramatically prolongs the duration of nicotine withdrawal-induced place aversion
Biol. Psychiatry
63
158-163
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Gkhan-Kelekci, N.; Yabanoglu, S.; Kepeli, E.; Salgin, U.; zgen, O.; Ucar, G.; Ye?ilada, E.; Kendi, E.; Yesilada, A.; Bilgin, A.A.
A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics
Bioorg. Med. Chem.
15
5775-5786
2007
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Ke, S.; Li, Z.; Qian, X.
1,3,4-Oxadiazole-3(2H)-carboxamide derivatives as potential novel class of monoamine oxidase (MAO) inhibitors: synthesis, evaluation, and role of urea moiety
Bioorg. Med. Chem.
16
7565-7572
2008
Rattus norvegicus
Manually annotated by BRENDA team
Aguiar, L.M.; Macedo, D.S.; Vasconcelos, S.M.; Oliveira, A.A.; de Sousa, F.C.; Viana, G.S.
CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats
Brain Res.
1191
192-199
2008
Rattus norvegicus (P19643), Rattus norvegicus, Rattus norvegicus Wistar (P19643)
Manually annotated by BRENDA team
Birgner, C.; Kindlundh-Hoegberg, A.M.; Oreland, L.; Alsioe, J.; Lindblom, J.; Schioeth, H.B.; Bergstroem, L.
Reduced activity of monoamine oxidase in the rat brain following repeated nandrolone decanoate administration
Brain Res.
1219
103-110
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Hewton, R.; Salem, A.; Irvine, R.J.
Potentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor
Clin. Exp. Pharmacol. Physiol.
34
1051-1057
2007
Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Dunkel, P.; Gelain, A.; Barlocco, D.; Haider, N.; Gyires, K.; Sperlagh, B.; Magyar, K.; Maccioni, E.; Fadda, A.; Matyus, P.
Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target
Curr. Med. Chem.
15
1827-1839
2008
Rattus norvegicus, Homo sapiens (P21397), Homo sapiens (P27338)
Manually annotated by BRENDA team
Izumi, T.; Iwamoto, N.; Kitaichi, Y.; Kato, A.; Inoue, T.; Koyama, T.
Effects of co-administration of antidepressants and monoamine oxidase inhibitors on 5-HT-related behavior in rats
Eur. J. Pharmacol.
565
105-112
2007
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
Savitha, S.; Naveen, B.; Panneerselvam, C.
Carnitine and lipoate ameliorates lipofuscin accumulation and monoamine oxidase activity in aged rat heart
Eur. J. Pharmacol.
574
61-65
2007
Rattus norvegicus
Manually annotated by BRENDA team
Olsen, H.T.; Stafford, G.I.; van Staden, J.; Christensen, S.B.; Jaeger, A.K.
Isolation of the MAO-inhibitor naringenin from Mentha aquatica L
J. Ethnopharmacol.
117
500-502
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Carotti, A.; Catto, M.; Leonetti, F.; Campagna, F.; Soto-Otero, R.; Mendez-Alvarez, E.; Thull, U.; Testa, B.; Altomare, C.
Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives
J. Med. Chem.
50
5364-5371
2007
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Sunal, S.G.; Yabanoglu, S.; Yesilada, A.; Ucar, G.
Monoamine oxidase inhibitory activities of novel 3,4-dihydroquinolin-(1H)-2-one derivatives
J. Neural Transm.
114
717-719
2007
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Wang, J.; Edmondson, D.E.
Do monomeric vs dimeric forms of MAO-A make a difference? A direct comparison of the catalytic properties of rat and human MAO-As
J. Neural Transm.
114
721-724
2007
Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens
Manually annotated by BRENDA team
Finberg, J.P.; Sader-Mazbar, O.
Modification of L-DOPA pharmacological activity by MAO inhibitors
J. Neural Transm.
114
801-805
2007
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Speiser, Z.; Fine, T.; Litinetsky, L.; Eliash, S.; Blaugrund, E.; Cohen, S.
Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline
J. Neural Transm.
115
107-116
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Ramadan, Z.B.; Wrang, M.L.; Tipton, K.F.
Species differences in the selective inhibition of monoamine oxidase (1-methyl-2-phenylethyl)hydrazine and its potentiation by cyanide
Neurochem. Res.
32
1783-1790
2007
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Bos taurus (P56560)
Manually annotated by BRENDA team
MacKenzie, E.M.; Grant, S.L.; Baker, G.B.; Wood, P.L.
Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition
Neurochem. Res.
33
430-436
2008
Rattus norvegicus
Manually annotated by BRENDA team
Carpene, C.; Iffiu-Soltesz, Z.; Bour, S.; Prevot, D.; Valet, P.
Reduction of fat deposition by combined inhibition of monoamine oxidases and semicarbazide-sensitive amine oxidases in obese Zucker rats
Pharmacol. Res.
56
522-530
2007
Rattus norvegicus
Manually annotated by BRENDA team
Prevot, D.; Soltesz, Z.; Abello, V.; Wanecq, E.; Valet, P.; Unzeta, M.; Carpene, C.
Prolonged treatment with aminoguanidine strongly inhibits adipocyte semicarbazide-sensitive amine oxidase and slightly reduces fat deposition in obese Zucker rats
Pharmacol. Res.
56
70-79
2007
Rattus norvegicus
Manually annotated by BRENDA team
Carpene, C.; Abello, V.; Iffiu-Soltesz, Z.; Mercier, N.; Feve, B.; Valet, P.
Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors
Pharmacol. Res.
57
426-434
2008
Rattus norvegicus
Manually annotated by BRENDA team
Upadhyay, A.K.; Edmondson, D.E.
Characterization of detergent purified recombinant rat liver monoamine oxidase B expressed in Pichia pastoris
Protein Expr. Purif.
59
349-356
2008
Rattus norvegicus (P19643)
Manually annotated by BRENDA team
Franke, R.M.; Belluzzi, J.D.; Leslie, F.M.
Gestational exposure to nicotine and monoamine oxidase inhibitors influences cocaine-induced locomotion in adolescent rats
Psychopharmacology
195
117-124
2007
Rattus norvegicus
Manually annotated by BRENDA team
Halberstadt, A.L.; Buell, M.R.; Masten, V.L.; Risbrough, V.B.; Geyer, M.A.
Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors
Psychopharmacology
201
55-66
2008
Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Osman, M.Y.; Osman, H.M.
Inhibitory effect of acetylcholine on monoamine oxidase A and B activity in different parts of rat brain
Arzneimittelforschung
58
493-496
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Upadhyay, A.K.; Borbat, P.P.; Wang, J.; Freed, J.H.; Edmondson, D.E.
Determination of the oligomeric states of human and rat monoamine oxidases in the outer mitochondrial membrane and octyl beta-D-glucopyranoside micelles using pulsed dipolar electron spin resonance spectroscopy
Biochemistry
47
1554-1566
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
Manually annotated by BRENDA team
MacKenzie, E.M.; Fassihi, A.; Davood, A.; Chen, Q.H.; Rauw, G.; Rauw, G.; Knaus, E.E.; Baker, G.B.
N-Propynyl analogs of beta-phenylethylidenehydrazines: synthesis and evaluation of effects on glycine, GABA, and monoamine oxidase
Bioorg. Med. Chem.
16
8254-8263
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21936)
Manually annotated by BRENDA team
Vilches-Herrera, M.; Miranda-Sepulveda, J.; Rebolledo-Fuentes, M.; Fierro, A.; Luehr, S.; Iturriaga-Vasquez, P.; Cassels, B.K.; Reyes-Parada, M.
Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors
Bioorg. Med. Chem.
17
2452-2460
2009
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Perez-Neri, I.; Montes, S.; Rios, C.
Inhibitory effect of dehydroepiandrosterone on brain monoamine oxidase activity: in vivo and in vitro studies
Life Sci.
85
652-656
2009
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Rattus norvegicus
Manually annotated by BRENDA team
Wang, J.; Edmondson, D.E.
High-level expression and purification of rat monoamine oxidase A (MAO A) in Pichia pastoris: comparison with human MAO A
Protein Expr. Purif.
70
211-217
2009
Rattus norvegicus, Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Iagodina, O.
Comparative study of catalytic properties of mink and rat liver monoamine oxidase
Zh. Evol. Biokhim. Fiziol.
44
570-576
2008
Rattus norvegicus, Neogale vison
Manually annotated by BRENDA team
Edmondson, D.E.; Binda, C.; Wang, J.; Upadhyay, A.K.; Mattevi, A.
Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases
Biochemistry
48
4220-4230
2009
Bos taurus, Homo sapiens, Mus musculus, Rattus norvegicus
Manually annotated by BRENDA team
Goekhan-Kelekci, N.; Simsek, O.O.; Ercan, A.; Yelekci, K.; Sahin, Z.S.; I?ik, S.; Ucar, G.; Bilgin, A.A.
Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors
Bioorg. Med. Chem.
17
6761-6772
2009
Rattus norvegicus
Manually annotated by BRENDA team
Luehr, S.; Vilches-Herrera, M.; Fierro, A.; Ramsay, R.R.; Edmondson, D.E.; Reyes-Parada, M.; Cassels, B.K.; Iturriaga-Vasquez, P.
2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors
Bioorg. Med. Chem.
18
1388-1395
2010
Homo sapiens, Rattus norvegicus
Manually annotated by BRENDA team
Shi, L.; Yang, Y.; Li, Z.L.; Zhu, Z.W.; Liu, C.H.; Zhu, H.L.
Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors
Bioorg. Med. Chem.
18
1659-1664
2010
Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Pisani, L.; Muncipinto, G.; Miscioscia, T.F.; Nicolotti, O.; Leonetti, F.; Catto, M.; Caccia, C.; Salvati, P.; Soto-Otero, R.; Mendez-Alvarez, E.; Passeleu, C.; Carotti, A.
Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, revers
J. Med. Chem.
52
6685-6706
2009
Rattus norvegicus
Manually annotated by BRENDA team
Wang, J.; Edmondson, D.E.
2H kinetic isotope effects and pH dependence of catalysis as mechanistic probes of rat monoamine oxidase A: comparisons with the human enzyme
Biochemistry
50
7710-7717
2011
Rattus norvegicus
Manually annotated by BRENDA team
Pisani, L.; Barletta, M.; Soto-Otero, R.; Nicolotti, O.; Mendez-Alvarez, E.; Catto, M.; Introcaso, A.; Stefanachi, A.; Cellamare, S.; Altomare, C.; Carotti, A.
Discovery, biological evaluation, and structure-activity and -selectivity relationships of 6'-substituted (E)-2-(benzofuran-3(2H)-ylidene)-N-methylacetamides, a novel class of potent and selective monoamine oxidase inhibitors
J. Med. Chem.
56
2651-2664
2013
Rattus norvegicus
Manually annotated by BRENDA team
Sergutina, A.V.; Rakhmanova, V.I.
Differences in monoamine oxidase activity in the brain of Wistar and August rats with high and low locomotor activity a cytochemical study
Bull. Exp. Biol. Med.
161
211-214
2016
Rattus norvegicus
Manually annotated by BRENDA team
Koc, G.?.; Tan, O.U.; Ucar, G.; Yildirim, E.; Erol, K.; Palaska, E.
Synthesis and monoamine oxidase inhibitory activities of some 3-(4-fluorophenyl)-5-aryl-n-substituted-4,5-dihydro-(1H)-pyrazole-1-carbothioamide derivatives
Drug Res.
64
591-598
2014
Rattus norvegicus (P19643), Rattus norvegicus (P21396)
Manually annotated by BRENDA team
Tzvetkov, N.T.; Stammler, H.G.; Neumann, B.; Hristova, S.; Antonov, L.; Gastreich, M.
Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors
Eur. J. Med. Chem.
127
470-492
2017
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens (P27338)
Manually annotated by BRENDA team
Sampaio, T.B.; Da Rocha, J.T.; Prigol, M.; Saraiva, R.A.; Nogara, P.F.; Stein, A.L.; da Rocha, J.B.; Zeni, G.; Nogueira, C.W.
4-Organoseleno-isoquinolines selectively and reversibly inhibit the cerebral monoamine oxidase B activity
J. Mol. Neurosci.
59
135-145
2016
Rattus norvegicus (P19643)
Manually annotated by BRENDA team
Yang, D.; Wang, R.; Zhu, J.; Cao, Q.; Qin, J.; Zhu, H.; Qian, S.
Synthesis, crystal structures, molecular docking, vitro monoamine oxidase-B inhibitory activity of transition metal complexes with 2-{4-[bis (4-fluorophenyl)methyl]piperazin-1-yl} acetic acid
J. Mol. Struct.
1128
493-498
2017
Rattus norvegicus (P19643), Homo sapiens (P27338)
-
Manually annotated by BRENDA team